전립선암 백신 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2024-2032년)

Growth Factors of prostate cancer vaccines Market

The global prostate cancer vaccines market is experiencing rapid growth due to rising disease prevalence, increasing awareness, and expanding adoption of personalized immunotherapies. According to recent insights, the market was valued at USD 490.4 million in 2024, is projected to reach USD 533.9 million in 2025, and is expected to grow to USD 1,183.6 million by 2032, reflecting a CAGR of 12.0% during the forecast period. North America dominated the market in 2024 with a 79.79% share, primarily due to well-established healthcare infrastructure, widespread access to immunotherapy, and higher awareness about prostate cancer treatment options.

Prostate cancer vaccines are therapeutic, targeting existing disease rather than prevention. The vaccines aim to activate immune cells capable of attacking prostate cancer cells, either to eradicate recurrent disease or delay disease progression. Currently, PROVENGE (Sipuleucel-T) by Dendreon Pharmaceuticals LLC. remains the only FDA-approved vaccine, reinforcing North America's leadership in the market. Rising demand for targeted, low-toxicity therapies and the limitations of traditional treatments such as hormone therapy and chemotherapy further propel market expansion.

According to the World Cancer Research Fund, 1,467,854 new prostate cancer cases were reported globally in 2022, emphasizing the urgent need for effective therapies. Immunotherapy offers durable responses with fewer side effects and can be combined with conventional treatments, enhancing its adoption in prostate cancer care.

Market Drivers and Opportunities

A key driver is the resistance to hormone therapy observed in advanced prostate cancer. Androgen deprivation therapy (ADT) reduces testosterone levels, yet tumors may develop resistance over time due to mutations in androgen receptors. Research from UCLA Jonsson Comprehensive Cancer Center in December 2023 revealed distinct basal and luminal prostate cells, highlighting that tumors less responsive to hormone therapy require alternative treatments, thereby increasing demand for vaccines.

Furthermore, the unmet need for personalized immunotherapies provides significant market opportunities. Companies are investing in novel vaccine candidates, including viral and DNA-based vaccines. In December 2024, Candel Therapeutics, Inc. reported positive Phase 3 results for CAN-2409 viral immunotherapy, combined with radiation therapy, demonstrating efficacy in intermediate-to-high-risk localized prostate cancer patients. Such developments highlight the market's growth potential and ongoing R&D investment.

Market Restraints and Challenges

The complex and lengthy administration of vaccines is a major restraint. Provenge requires leukapheresis, cell processing at a centralized facility, and reinfusion, spanning approximately four days. This labor-intensive process may limit adoption due to logistical challenges, patient compliance, and increased costs.

Additionally, the market faces regulatory challenges and high clinical trial failure rates. Strict regulations for cellular therapies often delay approvals and commercialization. For example, Ventac Partners' RV001 antigen-based vaccine failed its Phase 2 trial in May 2022 due to insufficient efficacy, illustrating the financial and developmental risks associated with prostate cancer vaccines.

Market Trends

A prominent trend is the development of DNA-based vaccines, designed to trigger potent anti-tumor immune responses. Vaccines such as MVI-118 by Madison Vaccines, Inc. target the androgen receptor ligand-binding domain for metastatic castration-sensitive prostate cancer. Preclinical and early clinical trials demonstrated safety, tolerability, and prolonged disease progression intervals, reflecting the growing role of nucleic acid technologies in immunotherapy. Integration with other therapies, including ADT and checkpoint inhibitors like Keytruda, is becoming increasingly common.

Segmentation Analysis

• By Product: PROVENGE (Sipuleucel-T) dominates, accounting for the largest market share in 2024 due to FDA approval and efficacy in advanced cases. The "others" segment is projected to grow steadily with new clinical-stage vaccines like PCA001 and VTP-850 entering development pipelines.
• By End User: Hospitals lead the market due to specialized infrastructure required for leukapheresis, cell processing, and vaccine administration. Specialty clinics and research centers are emerging as important adopters as immunotherapy access expands.

Regional Outlook

• North America: Valued at USD 391.3 million in 2024, the region benefits from a geriatric population at high risk, advanced infusion centers, and comprehensive reimbursement frameworks. The U.S. accounts for the majority of adoption.
• Europe: The second-largest market, driven by rising awareness campaigns and proactive testing programs such as the "Movember" initiatives in Hungary and Italy.
• Asia Pacific: Poised for the fastest growth due to increasing prostate cancer prevalence and the establishment of prostate care centers in countries like Australia.
• Latin America & Middle East & Africa: Exhibit slower growth due to high costs and limited awareness of prostate cancer vaccines.

Competitive Landscape

The market is highly consolidated, with Dendreon Pharmaceuticals LLC. leading due to PROVENGE. Other key players, including Barinthus Biotherapeutics, Candel Therapeutics, Inc., BioNTech, and Madison Vaccines, Inc., are advancing R&D pipelines and clinical trials to expand market presence and introduce novel vaccine candidates.

Conclusion

With a market size of USD 490.4 million in 2024, expected to reach USD 533.9 million in 2025, and projected to hit USD 1,183.6 million by 2032, the prostate cancer vaccines market is poised for substantial growth. Drivers include rising prevalence, resistance to hormonal therapies, and innovation in immunotherapy platforms, while regulatory complexity and administration challenges remain key hurdles. Continuous R&D, DNA-based vaccines, and expansion of treatment centers will shape market dynamics through 2032.

Segmentation By Product

• PROVENGE (sipuleucel-T)
• Others

By End User

• Hospitals
• Specialty Clinics
• Others

By Geography

• North America (By Product, End User, and Country )
  • U.S.
  • Canada
• Europe (By Product, End User, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific (By Product, End User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America (By Product, End User, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product, End User, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2024
• 4.2. Pipeline Analysis, by Key Players
• 4.3. Technological Advancements in Market
• 4.4. New Product Launches, by Key Players
• 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. PROVENGE (sipoleucel-T)
  • 5.1.2. Others
• 5.2. Market Analysis, Insights and Forecast - By End User
  • 5.2.1. Hospitals
  • 5.2.2. Specialty Clinics
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Latin America
  • 5.3.5. Middle East & Africa

6. North America Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. PROVENGE (sipoleucel-T)
  • 6.1.2. Others
• 6.2. Market Analysis, Insights and Forecast - By End User
  • 6.2.1. Hospitals
  • 6.2.2. Specialty Clinics
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. PROVENGE (sipoleucel-T)
  • 7.1.2. Others
• 7.2. Market Analysis, Insights and Forecast - By End User
  • 7.2.1. Hospitals
  • 7.2.2. Specialty Clinics
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.3.1. Germany
  • 7.3.2. U.K.
  • 7.3.3. France
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Rest of Europe

8. Asia Pacific Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. PROVENGE (sipoleucel-T)
  • 8.1.2. Others
• 8.2. Market Analysis, Insights and Forecast - By End User
  • 8.2.1. Hospitals
  • 8.2.2. Specialty Clinics
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. India
  • 8.3.4. Australia
  • 8.3.5. Rest of Asia Pacific

9. Latin America Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. PROVENGE (sipoleucel-T)
  • 9.1.2. Others
• 9.2. Market Analysis, Insights and Forecast - By End User
  • 9.2.1. Hospitals
  • 9.2.2. Specialty Clinics
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.3.1. Brazil
  • 9.3.2. Mexico
  • 9.3.3. Rest of Latin America

10. Middle East & Africa Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 10.1. Market Analysis, Insights and Forecast - By Product
  • 10.1.1. PROVENGE (sipoleucel-T)
  • 10.1.2. Others
• 10.2. Market Analysis, Insights and Forecast - By End User
  • 10.2.1. Hospitals
  • 10.2.2. Specialty Clinics
  • 10.2.3. Others
• 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.3.1. GCC
  • 10.3.2. South Africa
  • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles
  • 11.2.1. Dendreon Pharmaceuticals LLC.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. Financials (Based on Availability)
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. SWOT,Etc.
  • 11.2.2. Barinthus Biotherapeutics
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. Financials (Based on Availability)
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. SWOT,Etc
  • 11.2.3. Candel Therapeutics, Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. Financials (Based on Availability)
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. SWOT,Etc
  • 11.2.4. BioNTech
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. Financials (Based on Availability)
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. SWOT,Etc
  • 11.2.5. Madison Vaccines, Inc.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. Financials (Based on Availability)
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. SWOT,Etc